Tag: Moleculin Biotech

July 18, 2018

Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia

Moleculin Biotech (NASDAQ:MBRX) has announced that is has begun preclinical toxicology testing of its WP1732, a fully water-soluble STAT3 inhibitor...
June 6, 2018

Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa

Moleculin Biotech (Nasdaq:MBRX) a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 25, 2018

Moleculin Enters Agreement with BSP Pharmaceuticals for its Leukemia Drug Candidate

Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are...
April 4, 2018

Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial

Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are...
April 1, 2018

5 Top NASDAQ Biotech Stocks: Cardiome on Top

Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices.
March 28, 2018

Moleculin Biotech Reports Financial Results for the Year Ended December 31, 2017

Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are...